Investor Presentation • Jan 19, 2016
Investor Presentation
Open in ViewerOpens in native device viewer
| FY 14 | FY15 | Change | FY14 | FY15 | Change | ||
|---|---|---|---|---|---|---|---|
| Net Banking Income (Eu mn) |
284 | 408 | +44% | Net Loans to Customers (Eu bn) |
2.8 | 3.4 | |
| Net Result from Financial Operations (Eu mn) |
250 | 374 | +50% | AFS+HTM (Eu bn) |
5.1 | 3.2 | |
| Net Profit (Eu mn) |
96 | 162 | +69% | Total Funds and Deposits (Eu bn) |
7.7 | 6.1 | |
| Total Assets (Eu bn) |
8.3 | 7.0 | -16% | NPL ratio (Trade Receivables) |
1.3% | 1.1% | |
| Net Equity (Eu bn) |
438 | 573 | +31% | NPL Coverage ratio (Trade Receivables) |
86.4% | 87.9% | |
| CET 1 |
13.9% | 14.7% | RWA (Eu bn) |
2.8 | 3.3 |
B2B Trade finance with focus on SMEs & micro companies and Public Administration 4487 customers as of Dec 31,2015
Investment in retail Unsecured Distressed Loans portfolios Over 850.000 debtors/ individuals
Purchase of tax receivables arising from insolvency proceedings
FY2015 DRL results affected by nonrecurring operations for a total of 6.5 Mn
| B2B segment | Public Administration / Pharma segment |
||
|---|---|---|---|
| Target | Small or micro companies with medium to low credit standing |
• Large pharma companies working for NHS • New: Multi-utilities working for PA-Local Authorities |
|
| Customer base |
4.487 | SMEs | All major companies |
| and | 696 | Individual Businesses |
|
| segmentation by annual sales |
3.022 | Small <10 Eu Mn |
|
| 545 | Medium 10-50 Eu Mn | ||
| 224 | Large >50 Eu Mn | ||
| Type of product |
Factoring (i.e. loans after purchase of receivables) 80% with recourse |
More than half rapresented by outright purchase |
|
| Pricing/ profitability |
Interests average spread on 3 mth Euribor 2-7% (on loans) Fees on a monthly basis, on volumes of outstanding receivables: 0,10%-0,25% |
Purchase currently done till par. Profitability rapresented by local healthcare units late payment interest New:at discount |
|
| Competition | No real | competition | 2° largest player in NHS after Banca Farmafactoring |
| Results | FY 14 | FY 15 | % Change |
|---|---|---|---|
| Turnover Bn Eu |
8.3 | 10.1 | +21.8% |
| NBI Mn Eu | 156 | 159 | +2.0% |
| NBI/ Average Loans |
6.3% | 5.6% | |
| Provisions Mn Eu |
33 | 21 | -35.6% |
| Net Result from Financial Operations Mn Eu |
122 | 137 | +12.1% |
| Loans Bn Eu |
2.4 | 2.8 | +16.0% |
| NPL/Loans | 1.3% | 1.1% | |
| RWA Bn Eu |
1.8 | 1.8 | - |
| Target | Invest in Italian retail unsecured distressed loans |
|---|---|
| Customer base |
Over 850.000 debtors. Over 1.0 mln positions |
| Competitive advantage |
Sizeable owned portfolio integrated within a unique platform that drives our projected growing collection rate |
| DRL | FY 14 | FY 15 | % Change |
|---|---|---|---|
| NBI Mn Eu | 33 | 56 | +69% |
| Net Result from Financial Operations Mn Eu |
31 | 53 | +67% |
| Net Book Value Mn Eu |
135 | 354 | +162% |
| GBV Bn Eu |
5.6 | 8.2 | +45% |
| GBV purchased Bn Eu |
2.0 | 4.1 | +102% |
| GBV disposed Mn Eu |
219 | 1377 | +529% |
| RWA Mn Eu | 135 | 354 | +162% |
FY2015 DRL
Non-recurring operations in the segment:
Results affected at
| Target | Purchase of tax receivables arising mainly from insolvency proceedings |
|---|---|
| Customer base |
Bankruptcy courts in all domestic market |
| Competitive advantage |
Integrated collection platform that drives our projected growing collection rate |
| Tax receivables |
FY 14 | FY 15 | % Change |
|---|---|---|---|
| NBI Mn Eu | 11 | 20 | +85% |
| Net Result from Financial Operations Mn Eu |
11 | 20 | +77% |
| NBV Mn Eu | 119 | 131 | +9% |
| GBV Mn Eu | 168 | 191 | +13% |
| NBV/GBV | 71,2% | 68.6% | |
| RWA | 38 | 42 | +10.7% |
Strong balance sheet Over the last years Banca IFIS improved significantly its Capital Ratios and credit quality
| Fiscal year end |
FY14 | FY15 |
|---|---|---|
| Loans to banks Mn |
275 | 95 |
| Loans to customers Bn |
2.8 | 3.4 |
| Net securities Bn |
5.1 | 3.2 |
| Due to banks Bn |
2.3 | 0.7 |
| Due to customers Bn |
5.5 | 5.5 |
| Net equity Mn |
438 | 573 |
| Total assets/liabilities Bn |
8.3 | 7.0 |
| Euro |
10
Strong balance sheet Success retail funding for the new launch 3-4-5 yrs Rendimax formulas
| Funding Breakdown Eu Mn |
FY14 | FY15 | % change | Fiscal year end Eu |
FY14 | FY15 |
|---|---|---|---|---|---|---|
| Loans to banks |
275 | 95 | ||||
| Retail funding rendimax& |
3314 | 3113 | -6.1% | Mn | ||
| contomax | Loans to customers Bn |
2.8 | 3.4 | |||
| Wholesale funding |
||||||
| Due to banks | 2259 | 663 | -70.7% | Net securities Bn |
5.1 | 3.2 |
| Due to banks Bn |
2.3 | 0.7 | ||||
| Wholesale funding Repos |
2083 | 2279 | +9.4% | Due to customers | ||
| Bn | 5.5 | 5.5 | ||||
| Other payables |
86 | 95 | +10.2% | Net equity Mn |
438 | 573 |
| Total | ||||||
| assets/liabilities | 8.3 | 7.0 | ||||
| Bn |
| Eu Mn Nominal Value - Maturity |
Total amount |
% on total amount |
|---|---|---|
| From January to December 2016 |
759 | 23.6% |
| From January to December 2017 |
270 | 8.4% |
| From January to December 2018 |
1322 | 41.0% |
| From January to December 2019 |
675 | 20.9% |
| From January to December 2020 |
196 | 6.1% |
| Total | 3222 | 100.0% |
| Fiscal Year end |
FY14 | FY15 |
|---|---|---|
| Total shares Mn | 54 | 54 |
| EPS stated | 1.81 | 3.05 |
| BVPS | 8.27 | 10.81 |
| Dividend per share |
0.66 | 0.76 hypothesis |
| Dividend payout ratio % |
36.40 | 24.90 |
Share price as of 2015,31/12 28.83 Eu
This Presentation may contain written and oral "forward-looking statements", which includes all statements that do not relate solely to historical or current facts and which are therefore inherently uncertain. All forward-looking statements rely on a number of assumptions, expectations, projections and provisional data concerning future events and are subject to a number of uncertainties and other factors, many of which are outside the control of Banca IFIS. (the "Company"). There are a variety of factors that may cause actual results and performance to be materially different from the explicit or implicit contents of any forward-looking statements and thus, such forward-looking statements are not a reliable indicator of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable law. The information and opinions contained in this Presentation are provided as at the date hereof and are subject to change without notice. Neither this Presentation nor any part of it nor the fact of its distribution may form the basis of, or be relied on or in connection with, any contract or investment decision.
The information, statements and opinions contained in this Presentation are for information purposes only and do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to purchase or subscribe for securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments. None of the securities referred to herein have been, or will be, registered under the U.S. Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of the United States or in Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would be unlawful (the "Other Countries"), and there will be no public offer of any such securities in the United States. This Presentation does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or the Other Countries. Pursuant the consolidated law on financial intermediation of 24 February 1998 (article 154-bis, paragraph 2) Emanuel Nalli, in his capacity as manager responsible for the preparation of the Company's financial reports declares that the accounting information contained in this Presentation reflects the Banca IFIS's documented results, financial accounts and accounting records.
Neither the Company nor any member of Banca IFIS nor any of its or their respective representatives, directors or employees accept any liability whatsoever in connection with this Presentation or any of its contents or in relation to any loss arising from its use or from any reliance placed upon it.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.